Quality of Life Measures in Patients With Retinal Degeneration

Sponsor
University of Oxford (Other)
Overall Status
Completed
CT.gov ID
NCT02814435
Collaborator
(none)
90
1
15
6

Study Details

Study Description

Brief Summary

Inherited retinal degeneration (IRD) is a major cause of blindness and partial loss of vision cases in the UK and starts at an early age. The purpose of this observational study is to use the results of two questionnaires and a computerised test testing contrast sensitivity, to assess the impact of IRD on quality of life. This study will involve collecting data from patients with IRD, but also collecting data from normal controls.

Condition or Disease Intervention/Treatment Phase
  • Other: Questionnaire
  • Other: Computerised contrast sensitivity function test

Detailed Description

IRD presents a significant burden on the NHS as well as on the individual and families. IRDs are particularly difficult in a family situation due to guilt and other complex emotions related to inheritance patterns. Poorer mental health has been reported in patients with retinitis pigmentosa, manifesting in a range of ways including stress, depression and anxiety, particularly as the disease progresses. This is most probably caused by the uncertainty of the disease process and the progressive nature of the degeneration.

Recent work has reported that quality of life significantly deteriorates with a drop in visual field diameter of 20 degrees or a drop in visual acuity lower then LogMAR 0.3 (equivalent to 6/12). Contrast sensitivity is often used in conjunction with VA to assess visual capabilities. It is a measure of the ability to see reduced contrast and has a major impact on utility of vision. Relating contrast sensitivity function to quality of life will provide valuable information about whether this aspect of vision is a critical measure for patient health. This is especially important as novel treatments are being developed for the treatment of IRDs.

Study Design

Study Type:
Observational
Actual Enrollment :
90 participants
Observational Model:
Case-Control
Time Perspective:
Cross-Sectional
Official Title:
Quality of Life Measures in Patients With Retinal Degeneration
Actual Study Start Date :
Jul 1, 2016
Actual Primary Completion Date :
Oct 1, 2017
Actual Study Completion Date :
Oct 1, 2017

Arms and Interventions

Arm Intervention/Treatment
Patients

Patients with inherited retinal degeneration will answer two questionnaires and undergo a computerised contrast sensitivity function test.

Other: Questionnaire
The participants will answer two questionnaires. These are the NEI VFQ-25 and the DLTV (daily living tasks of vision).

Other: Computerised contrast sensitivity function test
This test involves the patient identifying whether bars on a screen are horizontal or vertical. It is designed to measure contrast sensitivity.

Normal controls

Normal controls recruited by advertising will answer two questionnaires and undergo a computerised test that assess contrast sensitivity function.

Other: Questionnaire
The participants will answer two questionnaires. These are the NEI VFQ-25 and the DLTV (daily living tasks of vision).

Other: Computerised contrast sensitivity function test
This test involves the patient identifying whether bars on a screen are horizontal or vertical. It is designed to measure contrast sensitivity.

Outcome Measures

Primary Outcome Measures

  1. Impact of inherited retinal degeneration on quality of life measures. [May 2016 to May 2017]

    This will be assessed by comparing questionnaire results between different inherited retinal degeneration types.This will be determined by using ANOVA testing to compare scores caused by different genetic mutations, allowing us to relate mutations causing central versus peripheral visual loss to the quality of life measures.

Secondary Outcome Measures

  1. Effect of contrast sensitivity function on quality of life. [May 2016 to May 2017]

    Contrast sensitivity function will be related to the questionnaire results using ANOVA testing & correlation analysis.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Participant is willing & able to give informed consent for participation in the study.

  • Male or female, aged 18 - 85.

  • A clinical or genetic diagnosis of retinal degeneration or normal age and sex-matched controls without known retinal disease.

  • Able to participate in visual function testing.

Exclusion Criteria:
  • The participant may not enter the study if any of the following apply:

    1. they have a pre-existing amblyopia or squint;
    1. they have any other retinal problems that may confound the measures assessed.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Oxford Eye Hospital Oxford United Kingdom OX3 9DU

Sponsors and Collaborators

  • University of Oxford

Investigators

  • Principal Investigator: Jasleen K Jolly, MSc, University of Oxford

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
University of Oxford
ClinicalTrials.gov Identifier:
NCT02814435
Other Study ID Numbers:
  • QoLMeasuresIRD
First Posted:
Jun 27, 2016
Last Update Posted:
Nov 13, 2018
Last Verified:
Nov 1, 2018
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Keywords provided by University of Oxford
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 13, 2018